Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sage Therapeutic Com (SAGE)

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,357,632
  • Shares Outstanding, K 58,382
  • Annual Sales, $ 1,114 M
  • Annual Income, $ 606,070 K
  • 60-Month Beta 2.01
  • Price/Sales 3.96
  • Price/Cash Flow N/A
  • Price/Book 1.90
Trade SAGE with:

Options Overview

Details
  • Implied Volatility 100.72%
  • Historical Volatility 48.13%
  • IV Percentile 89%
  • IV Rank 61.04%
  • IV High 126.12% on 04/05/21
  • IV Low 60.92% on 11/25/20
  • Put/Call Vol Ratio 0.77
  • Today's Volume 670
  • Volume Avg (30-Day) 791
  • Put/Call OI Ratio 1.13
  • Today's Open Interest 32,846
  • Open Int (30-Day) 9,695

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -1.98
  • Number of Estimates 14
  • High Estimate -1.42
  • Low Estimate -2.60
  • Prior Year -2.44
  • Growth Rate Est. (year over year) +18.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.00 +8.17%
on 03/25/21
81.00 -7.85%
on 04/06/21
-1.84 (-2.41%)
since 03/16/21
3-Month
68.23 +9.39%
on 03/05/21
93.61 -20.26%
on 01/21/21
-16.74 (-18.32%)
since 01/15/21
52-Week
29.73 +151.06%
on 04/17/20
98.39 -24.13%
on 01/15/21
+45.85 (+159.26%)
since 04/16/20

Most Recent Stories

More News
Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More

The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.

BIIB : 270.31 (-0.05%)
REGN : 502.60 (+1.61%)
GILD : 66.87 (+1.67%)
BMY : 65.46 (+1.58%)
SAGE : 74.64 (-1.14%)
Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study

Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.

BIIB : 270.31 (-0.05%)
MRNA : 170.81 (+6.84%)
RGEN : 213.30 (-0.13%)
SAGE : 74.64 (-1.14%)
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint

--SAGE-324 demonstrated a 36% reduction in upper limb tremor amplitude from baseline at Day 29 in the total studied population; in a more severe population (baseline TETRAS Upper Limb Item 4 >12), SAGE-324...

SAGE : 74.64 (-1.14%)
BIIB : 270.31 (-0.05%)
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

SAGE : 74.64 (-1.14%)
Sage Therapeutics to Present at the Stifel 3rd Annual CNS Day

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain,...

SAGE : 74.64 (-1.14%)
Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD

--After the initial 2-week zuranolone treatment, more than 70% of patients who received 30 mg and 80% of patients who received 50 mg achieved positive response at Day 15

SAGE : 74.64 (-1.14%)
Sage Therapeutics Announces Departure of Chief Operating Officer

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced...

SAGE : 74.64 (-1.14%)
Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress

--Progressed WATERFALL Study - now closed to enrollment - investigating zuranolone for as needed treatment of major depressive disorder with data anticipated in the first half of 2021

SAGE : 74.64 (-1.14%)
Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAGE : 74.64 (-1.14%)
Sage Therapeutics to Present at Upcoming Investor Conferences

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain,...

SAGE : 74.64 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Key Turning Points

3rd Resistance Point 79.26
2nd Resistance Point 78.11
1st Resistance Point 76.37
Last Price 74.64
1st Support Level 73.48
2nd Support Level 72.33
3rd Support Level 70.59

See More

52-Week High 98.39
Last Price 74.64
Fibonacci 61.8% 72.16
Fibonacci 50% 64.06
Fibonacci 38.2% 55.96
52-Week Low 29.73

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar